- Home
- DHT vs NEO Comparison
DHT vs NEO Comparison
Compare DHT & NEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DHT
- NEO
- Stock Information
- Founded
- DHT 2005
- NEO 2001
- Country
- DHT Bermuda
- NEO United States
- Employees
- DHT N/A
- NEO N/A
- Industry
- DHT Marine Transportation
- NEO Precision Instruments
- Sector
- DHT Consumer Discretionary
- NEO Health Care
- Exchange
- DHT Nasdaq
- NEO Nasdaq
- Market Cap
- DHT 1.7B
- NEO 902.1M
- IPO Year
- DHT 2005
- NEO 1999
- Fundamental
- Price
- DHT $11.22
- NEO $7.25
- Analyst Decision
- DHT Strong Buy
- NEO Buy
- Analyst Count
- DHT 4
- NEO 9
- Target Price
- DHT $13.75
- NEO $13.31
- AVG Volume (30 Days)
- DHT 1.8M
- NEO 2.1M
- Earning Date
- DHT 08-11-2025
- NEO 07-29-2025
- Dividend Yield
- DHT 8.47%
- NEO N/A
- EPS Growth
- DHT 4.76
- NEO N/A
- EPS
- DHT 1.10
- NEO N/A
- Revenue
- DHT $563,104,000.00
- NEO $672,361,000.00
- Revenue This Year
- DHT N/A
- NEO $13.97
- Revenue Next Year
- DHT $26.57
- NEO $11.36
- P/E Ratio
- DHT $10.03
- NEO N/A
- Revenue Growth
- DHT N/A
- NEO 10.10
- 52 Week Low
- DHT $8.67
- NEO $6.08
- 52 Week High
- DHT $12.32
- NEO $19.12
- Technical
- Relative Strength Index (RSI)
- DHT 49.32
- NEO 45.74
- Support Level
- DHT $10.79
- NEO $7.20
- Resistance Level
- DHT $11.45
- NEO $7.82
- Average True Range (ATR)
- DHT 0.26
- NEO 0.34
- MACD
- DHT -0.02
- NEO 0.05
- Stochastic Oscillator
- DHT 34.59
- NEO 41.24
About DHT DHT Holdings Inc.
DHT Holdings Inc is a crude oil tanker company. Its fleet trades internationally and consists of crude oil tankers in the VLCC. The group generates revenues from time charter and spot market operations. It operates through integrated management companies in Monaco, Norway, Singapore, and India. The company generates the majority of its revenue from the shipping revenues.
About NEO NeoGenomics Inc.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. It operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.